Close this search box.
Welcome to the Endologix suite
of health economics
and reimbursement resources.
Endologix supports healthcare professionals and patients through the reimbursement process.
This site contains information and resources you may need in that process.
The DETOUR System, an FDA-designated Breakthrough Device, was granted the New Technology Add-on Payment (NTAP) and the Transitional Pass-Through Payment (TPT) by the U. S. Centers for Medicare & Medicaid Services (CMS) for fiscal and calendar years 2024 through 2026.

The NTAP and TPT programs were created to:

Facilitate patient access for qualifying new medical technologies that substantially improve the diagnosis or treatment of Medicare beneficiaries.

Provide additional device reimbursement when the DETOUR System is used for eligible cases in the hospital inpatient and outpatient settings.

To obtain additional support navigating the
reimbursement process for the DETOUR System,
please contact us.

Endologix Reimbursement Support Center:

The reimbursement information provided above has been obtained from third party sources and is intended to be used as a general source of information only. It does not cover all possible patient care situations, payer rules, or scenarios. It is solely the provider’s responsibility to determine the proper medical products and services to be provided to individual patients, and to report the procedures and codes, if any, that most appropriately describe the products or services rendered. Endologix does not promise or guarantee coverage or payment by Medicare or any other payers by providing this information. The information does not constitute legal advice and no warranty regarding the completeness or accuracy of the information is made or implied. The information provided is subject to change without notice as reimbursement laws, regulations, rules and policies change frequently. Providers must seek advice from Medicare and/or other specific payers to obtain the most accurate, current and appropriate information related to pre-authorization, coverage, billing and reimbursement. Endologix specifically disclaims and rejects any liability or responsibility for any actions or consequences resulting from the use of this information.

©2023 Endologix LLC. All rights reserved. MM2760-US Rev 01